Groups

PD Dr. Cécile Gouttefangeas:

Research projects

______________________________________________________________________________________________________________________________________________________________________________________________________

Tumor-directed immune responses in cancer patients

  1. Identification of T-cell epitopes derived from newly identified tumor-associated antigens
  2. Antibody responses to tumor antigens
  3. Subsets of CD4+ and CD8+ T cells, immunosuppressive cell subsets within tumors (renal cell carcinoma, prostate carcinoma, glioma)
  4. Functional and phenotypic characterisation of PBMCs and TILs in renal cell carcinoma and prostate carcinoma
  5. Effect of standard therapies on the immune system of cancer patients (radiofrequency ablation)

 

T-cell monitoring of experimental immunotherapy for cancer patients

  1. CD4+ and CD8+ T-cell induction during peptide-based vaccination: phenotype and (multi)function; correlation with clinical course
  2. Establish, optimize, standardize and validate a palette of immunoassays as a platform for robust and sensitive immunomonitoring

 

Harmonisation of T-cell assays: international initiative from the CIMT Immunoguiding Program

  1. Proficiency panel program for T-cell assays (ELISPOT, HLA-multimer and intracellular cytokine staining)
  2. New technologies and detection of further immune cells (NK, Tregs, MDSCs)
  3. Dissemination of data (workshop program and CIP congress sessions)

 

We are supported by:

 

 

 

 

Figure 1

Figure 1:
Multicytokine production of CD4+ and CD8+ effectors in the peripheral blood (PBMC) or infiltrating the tumor (TIL) of a patient with renal cell carcinoma. T cells producing IL-10 are highlighted in black on IFN-γ+ and/or TNF-α+ effectors (Polychromatic flow cytometry, Attig et al, Cancer Res 2009;69:8412).

Figure 2

Figure 2:
Induction of vaccine-specific CD4+ T cells in one patient with prostate carcinoma after peptide-based vaccination (IFN-γ ELISPOT assay with HLA-class II-binding peptides).

Figure 3

Figure 3:
Phenotypic characterisation of vaccine induced CD8+ T cells using HLA-multimers and differentiation markers (Polychromatic flow cytometry)

Figure 4

Figure 4:
Identification of antigen-specific CD8+ T cells. Production of cytokine (IFN-γ and TNF-α) in primed healthy donor CD8+ T lymphocytes after stimulation with two HLA-A*0201-restricted peptides (Polychromatic flow cytometry)

Figure 5

Figure 5:

VITAL assay to assess the cytotoxic potential of tumor antigen specific CD8+ clones against peptide-loaded targets or trasnfectants expressing the relevant tumor antigen (Polychromatic flow cytometry, Laske et al, Cancer Immunol Res. 2013;190-200)